干燥综合征疾病活动及脏器损伤指数的研究进展被引量：10

Disease activity index and damage index in Sjogren's syndrome

下载PDF

导出

摘要干燥综合征(sjogren's syndrome,SS)是一种进展缓慢的结缔组织疾病,随时间延长会出现疾病的活动或脏器损伤,评估疾病的活动性及损伤情况对疾病的进一步治疗、评估疗效及了解预后甚为重要。目前为止,SS仍缺乏统一的评估病情状态的有效指标,1998年以来各国风湿病学专家在积极寻找评估的方法以用于临床实验和临床实践。目前用于临床的活动性指数主要有SS疾病活动性指数(SS disease activity index,SSDAI)、SS临床活动性指数(SS clinical activity index,SCAI)以及欧洲抗风湿病联盟SS疾病活动性指数(EULAR SS disease activity index,ESSDAI)三种,脏器损伤指数有SS疾病损伤指数(SS disease damage index,SSDDI)和SS损伤指数(SS damage index,SSDI)两种。此外,还有评估患者主观症状的欧洲抗风湿病联盟SS患者汇报指数(ESSPRI)与ESSDAI配合应用。几种活动性指数及损伤指数各有优缺点,总体来说,ESSDAI和ESSPRI是评估活动性最有希望的工具,也是目前国际上SS临床实验中应用最多的活动评估体系。相信在不久的将来,用于评估SS活动和损伤的国际公认指标将被提供。 Sjogren＇s syndrome is a slowly progressive connective tissue disease, disease activity or organ damage maybe e- merged with the extension of the course of disease. So it is very important to evaluate the activity and damage for the treatment and esti- mating prognosis. Till now no agreed valid index were accepted for evaluating disease. Now activity index used clinically mainly included SS disease activity index（ SSDAI）, SS clinical activity index（SCAI） and EULAR SS disease activity index （ESSDAI）. Damage index in- cluded SS disease damage index（SSDDI） and SS damage index（SSDI）. Moreover, EULAR Sjogren＇s syndrome patients report index （ESSPR1） ,which were used to evaluate subjective symptoms of patients,were used together with ESSDAI. The different type of activity indices and damage indices had each pros and cons. To sum up, ESSDAI and ESSPRI were the most promising and commonly used tool for evaluating the activity.

作者徐东赵岩

机构地区中国医学科学院北京协和医院风湿免疫科

出处《实用医院临床杂志》 2015年第5期22-26,共5页 Practical Journal of Clinical Medicine

关键词干燥综合征活动性损伤 Sjogren＇s syndrome Activity Damage

分类号 R593.2 [医药卫生—内科学]

引文网络
相关文献

参考文献12

1Robert I.Fox,Carla M.Fox.Sjogren's syndrome[M].New York: springer.2011.
2Bowman SJ,Sutcliffe N,Isenberg DA,et al.Sjogren's systemic clini- cal activity index(SC Al)-a systemic disease activity measure for use in clinical trials in primaiy sjogren's syndrome[J].Rheumatology (Oxford),2007,46:1845-1851.
3Barry RJ,Sutcliffe N,Isenberg DA,et al.The Sjogren's syndrome damage index-a damage index for use in clinical trials and observa- tional studies in primary sjogren's syndrome[J].Rheumatology,2008,47:1193-1198.
4Vitali C,Palombi G,BaIdini C,et al.Sjogren's syndrome disease damage index and disease activity index:scoring systems for the as- sessment of disease damage and disease activity in sjogren's syn- drome,derived from an analysis of a cohort of Italian patients[J]. Arthritis Rheum,2007,56:2223-2231.
5Seror R,Ravaud P,Bowman SJ,et al.EULAR Sjogren's task force. EULAR Sjogren ' s syndrome disease activity index:development of a consensus systemic disease activity index for primary sjogren;s syn- drome[J].Ann Rheum Dis,2010,69:1103-1109.
6Seror R,Ravaud P,Mariette X,et al.On behalf of the EULAR Sjogren's Task Force.EULAR Sjogren's syndrome patient reported index(ESSPRI):development of a consensus patient index for pri- mary sjogren's syndrome[J].Ann Rheum Dis,2011,70:968-972.
7Ng W-F,Bowman S,Griffiths B,The UKPSSR study group.Relation- ship between disease activity of primary Sjogren's syndrome and Pa- tient reported outcome e data from an interim analysis of the UK pri- mary Sjogren5S syndrome registry[J].Ann Rheum Dis,2011,70:510.
8Anna PR,Aike AK,Johannes WJB.Clinical applicability of the EU- LAR SjogrenjS syndrome disease activity index:a cumulative ESSDAI score adds in describing disease severity[J].Ann Rheum Dis,2012, 71(4);631.
9Meiners PM,Arends S,Brouwer E,et al.Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjo'' gren,s syndrome treated with rituximab[J].Ann Rheum Dis,2012, 71:1297-1302.
10Manuel RC,Pilar BZ,Roser S,et al.On behalf of the SS Study Group and Autoimmune Diseases Study Group(GEAS)of the Span- ish Society of Internal Medicine(SEMI).Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease ac- tivity index:analysis of 921 Spanish patients(GEAS-SS Registry)[J].Rheumatology,2014,53:321-331.